Century Therapeutics IPSC Cash Flow Statement (2020-2026)

NASDAQ IPSC
$2.13 +0.05 (+2.15%)
As of: Sep 4, 2026 · 3:12 PM EDT
Reported Financials

Century Therapeutics Quarterly Cash Flow Statement

Periods 25 quarters
Latest Jun 2026

Century Therapeutics reported cash from operations of -$19.83M and free cash flow of -$20.53M for the quarter ended Jun 2026, up 28.1% year over year. This cash flow statement covers 25 quarters of results from Jun 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow Statement Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-26.01M-28.15M-37.51M-30.99M-30.75M-31.68M-31.26M-33.29M-32.72M-39.40M-28.06M-31.21M-31.23M-8.13M76.56M-32.54M-34.42M-19.28M-21.66M-34.55M
Share-based CompensationStock Comp.
1.22M1.64M2.38M2.77M2.79M2.73M3.80M3.29M3.98M3.56M4.91M5.12M5.36M2.66M6.63M6.82M0.89M1.30M11.58M11.46M
Asset Writedowns and ImpairmentWritedown
4.22M12.14M4.33M6.76M
Cash from OperationsCash from Ops.
-23.98M-24.35M86.75M-25.56M-24.24M-22.91M-29.22M-19.25M-13.65M-26.23M-30.25M-27.33M-28.33M-24.22M-34.62M-27.59M-25.58M-16.10M-25.26M-19.83M
Depreciation, Depletion & Amortization
Amortizatization of IntangiblesAmort. of Intangibles
1.11M1.34M1.32M1.03M0.85M0.65M0.51M0.35M0.21M0.15M
Amortization of Deferred ChargesAmort. Deferred Charges
0.08M0.08M0.08M0.08M0.08M0.07M0.06M0.04M
Change in Working Capital
Change in Account PayablesChange Payables
-0.58M2.29M-1.50M-2.36M0.71M-1.63M-2.95M-0.51M3.99M-2.89M0.69M-1.88M-0.76M0.48M0.36M-0.36M-0.59M2.16M-1.62M1.67M
Change in Accured ExpensesChange Accured Exp.
0.38M-1.19M-1.17M2.27M1.73M1.13M-3.21M1.93M2.93M-2.39M-3.32M-0.24M2.25M2.91M-6.54M0.71M0.44M1.08M-3.96M1.16M
Investing Activities
Capital ExpendituresCapex
15.74M16.72M4.07M10.46M9.81M6.27M4.99M4.50M3.27M0.98M0.54M0.27M0.47M0.32M0.20M-0.14M0.58M0.69M
Change in Acquisitions & DivestmentsChange Acquisitions
14.76M38.01M63.09M57.20M98.86M52.33M79.16M110.49M64.98M29.27M47.17M29.87M51.57M48.18M43.29M42.52M35.89M37.82M28.66M34.37M
Cash from Investing ActivitiesCash from Investing
-147.05M-20.60M-44.04M12.52M22.66M-4.27M31.34M6.97M4.22M18.60M11.54M-33.86M39.20M30.61M27.93M32.54M24.67M22.36M-112.61M17.77M
Financing Activities
Other financing activitiesOther financing
-0.48M
Cash from Financing ActivitiesCash from Financing
-0.47M0.11M26.88M0.05M0.14M0.10M0.45M-10.12M0.30M-0.36M18.20M56.70M0.27M-0.60M0.12M0.05M126.62M0.31M
Change in Capital Stock
Net Shares Issued and RepurchasedNet Shares Issued
0.21M1.87M2.55M3.77M5.18M1.43M3.02M1.49M2.05M2.99M
Net Equity Issued and RepurchasedNet Equity Issued
0.07M0.05M0.14M0.10M0.45M0.12M0.30M-0.36M0.37M0.10M0.27M-0.60M0.12M0.05M0.20M0.35M
Additional items
Change in Cash
-171.50M-44.85M69.59M-12.99M-1.44M-27.09M2.57M-22.39M-9.13M-7.98M-0.51M-4.50M11.14M5.78M-6.57M4.95M-0.91M6.34M-11.25M-1.76M
Free Cash FlowFCF
-39.72M-41.07M82.69M-36.01M-34.05M-29.18M-34.21M-23.75M-16.91M-27.21M-30.79M-27.60M-28.33M-24.22M-35.10M-27.91M-25.78M-15.96M-25.85M-20.53M
Net Cash FlowNCF
-171.50M-44.85M69.59M-12.99M-1.44M-27.09M2.57M-22.39M-9.13M-7.98M-0.51M-4.50M11.14M5.78M-6.57M4.95M-0.91M6.31M-11.25M-1.76M